TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06705712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.
Description: All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing.
Study: NCT06721572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.
Study: NCT06727812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6208
Description: HRS-6208.
Study: NCT06730126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soquelitinib
Description: Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.
Study: NCT06716502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable CPAP efficacy
Description: The device will be tested in providing a PEEP comprised between 4-7,5 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable CPAP usability assessment
Description: The device usability will be evaluated in individual's self-experience tests, i.e., in conditions where the volunteer will self-apply the device.
Study: NCT06725732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
Study: NCT06710249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum/SPC flakes
Description: Egg yolk powder and specially processed cereals
Study: NCT06720675

Intervention type: PROCEDURE
Intervention: Hypothermic Oxygented Perfusion
Description: HOPE start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid (cold Belzer MPS solution) during back-table preparation. Hepatic perfusion was performed through the vein leads to a pressure of 3-5 mmHg. Organ were treated with continuous HOPE until transplant and the perfusion was continuously monitored and data downloaded in a USB memory.

Intervention type: PROCEDURE
Intervention: Static Cold Storage
Description: Liver grafts are stored in sterile organ bags with cold Belzer or Celsior solution and kept in ice at 4°C.
Study: NCT06720909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The standard 8-week MBSR program will be led by certified MBSR instructors from the UCSD Center for Mindfulness. The program content will consist of a variety of mindfulness and meditative techniques, such as sitting meditation, body scans, and mindful yoga. Participants will engage in weekly sessions via Zoom, participation in group discussions, and honing their other mindfulness skills. Throughout the program, participants will be instructed to commit to a daily mindfulness meditation practice lasting approximately 45 minutes, at least 6 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo (OLP)
Description: The placebo pills will be size #1 capsules filled with (1) microcrystalline cellulose, a common inert excipient for pharmaceuticals, and (2) 25 mg riboflavin tracer. Participants will be informed that the placebo pills are inactive substances, like sugar pills, and contain no active medication. Then, they will watch a brief introduction video which will cover four main discussion points: (1) the placebo effect can be powerful and can have beneficial effects for diverse symptoms, (2) the body can respond to taking placebo pills automatically despite the knowledge that it is placebo (e.g., Pavlov's dogs), (3) a positive attitude or expectation can be beneficial but is not necessary, and (4) taking the pills faithfully throughout the intervention period is critical.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR+OLP
Description: This condition involves a combination of interventions, where participants will receive both MBSR and OLP treatments.
Study: NCT06722157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegcetacoplan
Description: Pegcetacoplan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham comparator to BI 771716
Description: Sham comparator to BI 771716
Study: NCT06730594

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VL-BK-02 (25 billion CFU/Capsule)
Description: One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Microcrystalline Cellulose - 375 mg/capsule)
Description: One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
Study: NCT06731478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered.
Study: NCT06730945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral isosorbide mononitrate 4+ amlodipine
Description: Oral isosorbide mononitrate 40mg (if unable to tolerate, 20mg) once daily + amlodipine 5mg (if unable to tolerate, 2.5mg) once daily for 24 weeks after CABG
Study: NCT06704763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Administered orally
Study: NCT06733935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion
Study: NCT06732453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)
Description: Two one-hour chair-based yoga sessions that will include gentle movements, breathing practices, and meditation, along with home practice.
Study: NCT06733363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Participate in POW-R Health Only/Core program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone- Based Intervention
Description: Receive live phone calls
Study: NCT06729450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DispersinB Acne Cleanser
Description: DispersinB Acne Cleanser, strength: 80 ug/g, topical gel
Study: NCT06728462

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Amorphous calcium carbonate
Description: The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Amorphous calcium carbonate
Description: The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
Study: NCT06723613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.~Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH-Breastfeeding Record System, IMDAT: Breast milk intake level assessment tool scales will be applied to mothers before exercise (8th week after birth) and after exercise (14th week).
Study: NCT06723145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: perioperative aspirin continuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin interruption
Description: Aspirin interruption 5-7 days before surgery
Study: NCT06695156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly
Study: NCT06733675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledaborbactam etzadroxil
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten-ledaborbactam etzadroxil
Description: Fixed Dose Combination (FDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten-ledaborbactam etzadroxil
Description: Fixed Dose Combination (FDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten-ledaborbactam etzadroxil
Description: Fixed Dose Combination (FDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten-ledaborbactam etzadroxil
Description: Fixed Dose Combination (FDC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 mg capsule
Study: NCT06741111

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06736691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside (BAY 44-4400)
Description: Treatment with single dose of oral 15 mg emodepside

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo of emodepside
Description: Treatment with single dose of oral emodepside matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: similar placebo to mebendazole
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Study: NCT06736808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout Written at Below a Sixth Grade Reading Level
Description: Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout Written at Above a Sixth Grade Reading Level
Description: Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
Study: NCT06736262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: No additional details needed
Study: NCT06742931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of antiplatelet agent group
Description: In this group, antiplatelet monotherapy will be discontinued at the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, all antiplatelet agents will be discontinued after randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of antiplatelet agent group
Description: In this group, lifelong antiplatelet monotherapy will be continued after the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, DAPT will be changed to single antiplatelet therapy (aspirin or clopidogrel). The choice between aspirin or clopidogrel will be determined by the physician's discretion.
Study: NCT06742281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA (CVXGA50)
Description: CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COMIRNATY®
Description: COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
Study: NCT06516965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06658535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dodecafluoropentane (0.025 mL/kg)
Description: dodecafluoropentane (0.025 mL/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dodecafluoropentane (0.032 mL/kg)
Description: dodecafluoropentane (0.032 mL/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dodecafluoropentane (0.050 mL/kg)
Description: dodecafluoropentane (0.050 mL/kg)
Study: NCT06745271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-tebapivat
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C2,15N3]-tebapivat
Description: Intravenous Solution
Study: NCT06740435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Telemedicine for Type 2 Diabetes
Description: Telemedicine-based endocrinology specialty care for type 2 diabetes with multidisciplinary diabetes care team support including pre-visit preparation, in-visit support and self-management education, and post-visit follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Telemedicine Endocrinology Care for T2D
Description: Routine telemedicine-based endocrinology specialty care for type 2 diabetes, generally consisting of synchronous virtual visit with an endocrinologist and additional support including self-management education on an individualized basis.
Study: NCT06741228

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that is designed to have no therapeutic value

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Study: NCT06745908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANKTIVA
Description: ANKTIVA 1.2 mg SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg IV

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV
Study: NCT06740227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Balance Training
Description: Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Training
Description: one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
Study: NCT06736795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All participants will be instructed in a progressive Achilles tendon loading exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants will be instructed in a progressive Achilles tendon loading exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.
Study: NCT06735144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FH-006
Description: Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FH-006
Description: administered once every 3 weeks (Q3W), with a treatment period of 21 days
Study: NCT06740747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation
Description: Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta-burst stimulation
Description: Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
Study: NCT06740201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipepofol
Description: Adjust plasma target-controlled concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipepofol
Description: Adjust plasma target-controlled concentration